Ramos-Peñafiel CO, Tovilla-Ruiz CK, Galván-Flores F, Castañeda-Rodríguez R, Álvarez EMÁ, Durán-Guzmán R, Sánchez-Carranza R, Salcedo-Roldán M, Santoyo-Sánchez A, Martínez-Murillo C

Language: Spanish
References: 19
Page: 50-56
PDF size: 565.03 Kb.

ABSTRACT

Background: Hyperkalemia is the most common ion disorder in patients with chronic kidney disease, the comparative assays between existing treatment strategies are scarce, especially in adults.
Objective: To evaluate the efficiency of hiperK-cocktail in the management of hyperkalemia, compared to the standard strategy of insulindextrose.
Material and method: A randomized clinical trial was done in two groups with relation 2:1 in favor of the innovative proposal; group A received insuline-dextrose; group B received hiperK-cocktail (1,000 mL of 10% dextrose + sodium bicarbonate [44.6 mEq] + 20 units of regular insulin). Adults with chronic kidney disease and serum potassium between 6.0-8.6 mEq/L were included, excluding cases who received renal function replacement therapy.
Results: In total, 50 patients were included, with 45.9 years old as average age. The overall mean of potassium at enrollment was 6.7 mEq/L (6.01-8.2 range), similar between both groups. Both strategies decreased the serum potassium significantly (p=0.000) regarding the basal mean of the same group, but without statistical difference in the intergroup comparative at 30 minutes (6.18 vs 6.19), 60 minutes (6.30 vs 5.96) neither 4 hours (6.07 vs 5.64). The hiperK-cocktail group obtained a lower overall mean of potassium (5.97 vs 6.2, p=0.001), and higher number of complete remissions since the 60 minutes (63.3% vs 35%, p=0.046).
Conclusions: Our results agree with other studies and indicate that hiperK-cocktail is as effective as standard therapy, obtaining greater number of complete remissions of hyperkalemia, especially after one hour of administration.

REFERENCES

1. Kossmann RJ. From CKD to ESRD: a tale of two transitions. Adv Chronic Kidney Dis 2011;18:439-442.

2. Collins AJ, Foley RN, Chavers B, Gilbertson D, et al. US renal data system 2013 Annual Data Report. Am J Kidney Dis 2014;63:7.

3. Chawla LS, Herzog CA, Costanzo MR, Tumlin J, et al. Viewpoint: Proposal for a functional classification system of heart failure in patients with end-stage renal disease: Proceedings of the Acute Dialysis Quality Initiative (ADQI) XI Workgroup. J Am Coll Cardiol 2014;63:1246-1252.

4. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16:101-105.

5. Raymond CB, Sood AR, Wazny LD. Treatment of hyperkalemia in patients with chronic kidney disease–a focus on medications. CANNT J 2010;20:49-53.

6. Dussol B. Potassium physiology, hypokalaemia and hyperkalaemia. Nephrol Ther 2010;6:180-199.

7. Pepin J, Shields C. Advances in diagnosis and management of hypokalemic and hyperkalemic emergencies. Emerg Med Pract 2012;14:1-17.

8. Mushiyakh Y, Dangaria H, Qavi S, Ali N, et al. Treatment and pathogenesis of acute hyperkalemia. J Community Hosp Intern Med Perspect 2012;1. Disponible en: http://dx.doi. org/10.3402%2Fjchimp.v1i4.7372 (Consultado el 15 marzo de 2014).

9. Raymond CB, Sood AR, Wazny LD. Treatment of hyperkalemia in patients with chronic kidney disease–a focus on medications. CANNT J 2010;20:49-53.

10. Chothia MY, Halperin ML, Rensburg MA, Hassan MS, Davids MR. Bolus administration of intravenous glucose in the treatment of hyperkalemia: a randomized controlled trial. Nephron Physiol 2014;126:1-8.

11. Oschman A, Gansen A, Kilbride H, Sandritter T. Safety and efficacy of two potassium cocktail formulations for treatment of neonatal hyperkalemia. Ann Pharmacother 2011;45:1371-1377.

12. Ostovar H, Jones J, Brown M. Best evidence topic report. Nebulised levalbuterol or albuterol for lowering serum potassium. Emerg Med J 2005;22:366-367.

13. Pancu D, LaFlamme M, Evans E, Reed J. Levalbuterol is as effective as racemic albuterol in lowering serum potassium. J Emerg Med 2003;25:13-16.

14. Lexchin J. Treating hyperkalemia. Lancet 2003;361:616.

15. Mahoney BA, Smith WA, Lo DS, Tsoi K, et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005;18:3235.

16. Liou HH, Chiang SS, Wu SC, Yang WC, Huang TP. Intravenous infusion or nebulization of salbutamol for treatment of hyperkalemia in patients with chronic renal failure. Zhonghua Yi Xue Za Zhi (Taipei) 1994;53:276-281.

17. Mahajan SK, Mangla M, Kishore K. Comparison of aminophylline and insulin-dextrose infusions in acutetherapy of hyperkalemia in end-stage renal disease patients. J Assoc Physicians India 2001;49:1082-1085.

18. Allon M, Takeshian A, Shanklin N. Effect of insulin-plusglucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int 1993;43:212-217.

19. Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron 1996;72:476-842.